C. diff. Spores and More

Join us as guests Sue Barnes, RN, BSN, CIC, FAPIC, Independent and Board Certified Clinical Consultant in Infection Control and Prevention and APIC Fellow with Lori Strazdas, MPH - Public Health Liaison with Clorox Healthcare discuss the importance of C. difficile and how difficult of an infection it is to manage not only for patients but for the caretakers and loved ones. Before the patient leaves the hospitals, it is critical to understand the proper steps to reduce the spread of C. difficile spores in the home environment. In this episode, learn why it is important to focus on the home environment during and after a C. difficile infection and what can be done to reduce the risk of transmission and recurrence. Our guests will be discussing the types of disinfecting products that can be utilized to effectively kill C. diff. spores and how to use the products properly to accomplish this in the home environment.

Join us as guests Sue Barnes, RN, BSN, CIC, FAPIC, Independent and Board Certified Clinical Consultant in Infection Control and Prevention and APIC Fellow with Lori Strazdas, MPH - Public Health Liaison with Clorox Healthcare discuss the importance of C. difficile and how difficult of an infection it is to manage not only for patients but for the caretakers and loved ones. Before the patient leaves the hospitals, it is critical to understand the proper steps to reduce the spread of C. difficile spores in the home environment. In this episode, learn why it is important to focus on the home environment during and after a C. difficile infection and what can be done to reduce the risk of transmission and recurrence. Our guests will be discussing the types of disinfecting products that can be utilized to effectively kill C. diff. spores and how to use the products properly to accomplish this in the home environment.

Listen in as our guests Dr. Caterina Oneto, MD and Dr. Paul Feuerstadt, MD both specializing in Gastroenterology -- will be discussing IBD and what Inflammatory bowel disease (IBD) involves, including the chronic inflammation of all or part of the digestive tract. The Physicians will also be discussing signs and symptoms and diagnosing of a C. difficile Infection (CDI) along with the preventative measures, treatments available, and environmental safety products that can be utilized in a home setting. If you have any questions for the Physicians, e-mail us before the live broadcast at [email protected] and we will share the answers during the program.

Join us with our guest Linda Jablonski, MSN, BSN, BC-RN, as we discuss becoming an effective self-advocate and how to advocate for others. It is about asking the right questions, when to seek clarification when topics are not understood and how to make sure their values and goals are part of the discussion.For a significant percentage of people facing any serious illness, becoming an effective self-advocate poses a range of challenges. Get a piece of paper and pencil ready, the iPad works well also, and a few notes will go a long way in the path of advocating in healthcare.

Listen in as our guest Shelby Lassiter, BSN,RN,CPHQ,CIC, Infection Preventionist, joins us to discuss the many ways on how to maintain infection control in a home environment while treating a C. diff. infection. That means how to eliminate the C. diff. spores and more!

Sanofi Pasteur's Dr. Christian Felter, MD is Associate VP, Global Medical Expert for Nosocomial Vaccines for Sanofi Pasteur based in Lyon, France. His focus is on their investigative Clostridium difficile vaccine.

Dr. Patricia J. Freda Pietrobon, PhD, Associate Vice President, R&D, Sanofi Pasteur, has over 25 years of experience in the Vaccine & Diagnostic industries and more then 20 years in leadership roles focusing on research & development of new vaccines.

Dr. Guy de Bruyn, Director for Clinical Development at Sanofi Pasteur, overseeing a large phase III vaccine trial for the prevention of Clostridium difficile infection in some 19 countries on 5 continents around the world that started in the U.S. in 2013. These three Sanofi Pasteur professionals will discuss the background of acquiring a C.difficile infection, Sanofi Pasteur's vaccine (Cdiffense) program, and the data from the preventative vaccine in Phase II.

Listen in as our guest Shelby Lassiter, BSN,RN,CPHQ,CIC, Infection Preventionist, joins us to discuss the many ways on how to maintain infection control in a home environment while treating a C. diff. infection. That means how to eliminate the C. diff. spores and more!

Join us with guests Jenna Petelle Arsenault, MSW, RN and Janice Howard,Director of the Life Care – Private Duty Program at Cornerstone VNA. Both Jenna and Janice will be discussing the importance of the Caregiver and description of a Caregiver's role. We know that with an increasingly aging population in all developed societies, the role of caregiver has been increasingly recognized as an important one, both functionally and economically. Many organizations which provide support for persons with disabilities have developed various forms of support for carers as well.

Join our guest, Linda Jablonski, MS,BSN,RN-BC as we discuss caring for patients and families in the home care setting, Nurses specializing in Home Care, and preventing infections within the home environment. There will be something new to learn during this episode from team members to patients.

Join us as Dr. Dale Gerding, MD, an Infectious Disease specialist, researcher, professor, hospital epidemiologist, and one of the leading international experts on Clostridium diffiicle (C.diff.), will discuss his patented non-toxigenic Clostridium difficile (NTCD-M3) technology for the prevention and treatment of a C. diff. infection. Dr.Gerding currently owns patents and all rights to the development, manufacturing, regulatory, and clinical trial data for NTCD-M3. The lead pharmaceutical product, NTCD-M3, incorporating this technology has already completed Phase 1 & 2 Clinical Trials, has FDA Fast Track approval, is expected to be eligible for Breakthrough Therapy Designation by the FDA for a Phase 3 Clinical Trial, and to be eligible for Reference Product Exclusivity for 12 years for an approved biologics license application.